Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Ras Gene02:38

The Ras Gene

5.7K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K
The Ras Gene02:38

The Ras Gene

2.3K
2.3K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

4.4K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.4K
Abnormal Proliferation02:23

Abnormal Proliferation

4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generation of Functional Oligodendrocyte Progenitor Cells Through Serial Replating of iPSC-Derived NPC Spheres.

Cells·2026
Same author

Habitual Ultra-processed Food Intake Is Associated with Gut Dysbiosis and Pro-inflammatory Metabolite Profiles in Korean Patients with IBD.

Digestive diseases and sciences·2026
Same author

Population Pharmacokinetics and Model-Informed Precision Dosing of Lenalidomide Incorporating Total and Unbound Plasma Concentrations in Renally Impaired Patients with Multiple Myeloma.

Drug design, development and therapy·2026
Same author

Advancing Small-Molecule Immunotherapy Through Polymeric Micelle Delivery.

Pharmaceutics·2026
Same author

Korean Medical Consultation With Open-Weight Large Language Models: Pilot Comparative Evaluation of Retrieval-Augmented Generation With Metadata Filtering.

JMIR formative research·2026
Same author

High-tech, high-touch physical education: drone soccer as a sustainable sport activity for sport-marginalized students.

Frontiers in psychology·2026
Same journal

Trophoblastic-Differentiated Urothelial Carcinoma: Real-World Sequencing and Clinical Implications.

Clinical genitourinary cancer·2026
Same journal

Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.

Clinical genitourinary cancer·2026
Same journal

Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature.

Clinical genitourinary cancer·2026
Same journal

Beyond the Hazard Ratio: Time-Varying Treatment Effects in Genitourinary Cancer Trials.

Clinical genitourinary cancer·2026
Same journal

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

Clinical genitourinary cancer·2026
Same journal

Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA Profiling.

Clinical genitourinary cancer·2026
See all related articles
  1. Home
  3. Association Between Proto-oncogene N-ras Transcript Level And Overall Survival In Node-negative Muscle-invasive Bladder Cancer.
  1. Home
  3. Association Between Proto-oncogene N-ras Transcript Level And Overall Survival In Node-negative Muscle-invasive Bladder Cancer.

Related Experiment Video

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

9.8K

Association Between Proto-Oncogene N-RAS Transcript Level and Overall Survival in Node-Negative Muscle-Invasive

Donghyun Kim1, Yasser Ged2, Petros Grivas3

  • 1Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Health Care, Iowa City, IA.

Clinical Genitourinary Cancer
|April 29, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

High N-RAS expression in muscle-invasive bladder cancer (MIBC) correlates with poorer survival. Low N-RAS may indicate a benefit from cisplatin chemotherapy, suggesting N-RAS as a potential prognostic biomarker in MIBC.

Keywords:
CisplatinGene expressionPrognostic biomarkerUrothelial carcinoma of the bladder

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.1K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.4K

Related Experiment Videos

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

9.8K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.1K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.4K

Area of Science:

  • Oncology
  • Genetics
  • Biomarker Discovery

Background:

  • Muscle-invasive bladder cancer (MIBC) treatment advances highlight the need for prognostic biomarkers.
  • While H-RAS and K-RAS mutations are common in bladder cancer, N-RAS mutations are rare, but N-RAS overexpression has been observed.
  • The clinical significance of N-RAS overexpression in MIBC remains unclear.

Purpose of the Study:

  • To investigate the prognostic implications of N-RAS expression in muscle-invasive bladder cancer (MIBC).
  • To explore the association between N-RAS expression levels and patient survival outcomes.
  • To determine if N-RAS expression influences response to cisplatin-based chemotherapy.

Main Methods:

  • Analysis of The Cancer Genome Atlas Bladder Cancer dataset (n=411), focusing on node-negative MIBC (n=218).
  • Stratification of patients into 'high' and 'low' N-RAS transcript expression groups based on the cohort median.
  • Survival analyses, including overall survival, were performed using these stratifications.

    • Main Results:

    • High N-RAS expression was linked to inferior 5-year overall survival in node-negative MIBC (HR 1.91, P=.007).
    • A significant overall survival benefit from cisplatin-based chemotherapy was observed in the low N-RAS group (HR 0.28, P=.019), but not in the high N-RAS group.
    • The high N-RAS group exhibited significantly higher CD274 (PD-L1) transcript levels compared to the low N-RAS group (P < .0001).

    Conclusions:

    • N-RAS transcript levels may serve as a prognostic indicator for node-negative MIBC.
    • Lower N-RAS expression levels could be associated with improved survival outcomes when treated with cisplatin-based chemotherapy.
    • N-RAS expression warrants further investigation as a predictive biomarker in MIBC treatment strategies.